Literature DB >> 3147478

Nicotine tolerance: an analysis of the time course of its development and loss in the rat.

A C Collins1, E Romm, J M Wehner.   

Abstract

The time course of the development and loss of tolerance to nicotine was measured in female rats that were injected subcutaneously (SC), twice daily with 1.6 mg/kg nicotine. Tolerance to nicotine-induced decreases in locomotor activity and body temperature were observed. Tolerance to the effects of nicotine on both of these measures developed rapidly, with maximal changes occurring within 2-4 days after initiation of treatment. The binding of L-[3H]-nicotine was measured in six brain regions. Chronic nicotine treatment resulted in increases in binding in most brain regions. The increase in binding correlated significantly with the development of tolerance. Rats that had been injected chronically with nicotine did not lose their tolerance throughout a 7-day post-treatment test period. Control levels of binding were regained in all of the brain regions except cortex by 7 days after nicotine treatment was stopped. These findings indicate that changes in receptor binding may relate to the development of tolerance but the retention of tolerance is clearly not related to the number of brain nicotinic receptors, unless nicotine-induced decreases in body temperature and locomotor activity are controlled by cortical [3H]-nicotine binding sites.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147478     DOI: 10.1007/bf02431526

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Tolerance development to the arousal effects of nicotine.

Authors:  J E Hubbard; R S Gohd
Journal:  Pharmacol Biochem Behav       Date:  1975 May-Jun       Impact factor: 3.533

2.  Nature of nicotine binding to rat brain P2 fraction.

Authors:  J W Sloan; G D Todd; W R Martin
Journal:  Pharmacol Biochem Behav       Date:  1984-06       Impact factor: 3.533

3.  Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin.

Authors:  M J Marks; J A Stitzel; E Romm; J M Wehner; A C Collins
Journal:  Mol Pharmacol       Date:  1986-11       Impact factor: 4.436

4.  In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs.

Authors:  R D Schwartz; K J Kellar
Journal:  J Neurochem       Date:  1985-08       Impact factor: 5.372

5.  [3H]acetylcholine and [3H](-)nicotine label the same recognition site in rat brain.

Authors:  A M Martino-Barrows; K J Kellar
Journal:  Mol Pharmacol       Date:  1987-02       Impact factor: 4.436

6.  The effects of nicotine on locomotor activity in non-tolerant and tolerant rats.

Authors:  P B Clarke; R Kumar
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

7.  Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine.

Authors:  M J Marks; A C Collins
Journal:  Pharmacol Biochem Behav       Date:  1985-02       Impact factor: 3.533

8.  Exposure to nicotine enhances the behavioral stimulant effect of nicotine and increases binding of [3H]acetylcholine to nicotinic receptors.

Authors:  C Ksir; R Hakan; D P Hall; K J Kellar
Journal:  Neuropharmacology       Date:  1985-06       Impact factor: 5.250

9.  Subchronic treatment of rats with nicotine: effects on tolerance and on [3H]acetylcholine and [3H]nicotine binding in the brain.

Authors:  C Larsson; L Nilsson; A Halén; A Nordberg
Journal:  Drug Alcohol Depend       Date:  1986-05       Impact factor: 4.492

10.  Time course study of the effects of chronic nicotine infusion on drug response and brain receptors.

Authors:  M J Marks; J A Stitzel; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1985-12       Impact factor: 4.030

View more
  23 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 3.  Cellular events in nicotine addiction.

Authors:  Rachel E Penton; Robin A J Lester
Journal:  Semin Cell Dev Biol       Date:  2009-01-20       Impact factor: 7.727

Review 4.  Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.

Authors:  E L Ochoa; L Li; M G McNamee
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

5.  Tolerance to nicotine in mice lacking alpha7 nicotinic receptors.

Authors:  C Naylor; D Quarta; C Fernandes; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

6.  Chronic ethanol or nicotine treatment results in partial cross-tolerance between these agents.

Authors:  J B Burch; C M de Fiebre; M J Marks; A C Collins
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats.

Authors:  Kelen Freitas; F Ivy Carroll; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.157

8.  Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

9.  Characteristics of tail-tremor induced by nicotine in rats.

Authors:  K Suemaru; R Oishi; Y Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

10.  Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug.

Authors:  Lorinda K Baker; Danyan Mao; Henry Chi; Anitha P Govind; Yolanda F Vallejo; Michael Iacoviello; Stacy Herrera; James J Cortright; William N Green; Daniel S McGehee; Paul Vezina
Journal:  Eur J Neurosci       Date:  2013-01-21       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.